2021 Volume 41 Issue 4 Pages 173-182
Atrial antitachycardia pacing（A-ATP）has been reported to reduce atrial tachyarrhythmias（AT/AF）burden. However, little is known about predictive factors of AT/AF burden reduction. The aim of this study was to determine factors of AT/AF burden reduction. Twenty-two patients treated with new-generation A-ATP（Reactive ATP, Medtronic Inc., Minneapolis, MN, USA）were included in this study, and baseline characteristics, intracardiac electrocardiograms（ECGs）, and a 12-lead ECGs, Cardiac echography, BNP were obtained. An AT/AF burden reduction of more than 50％ was defined as effective. Patients with baseline AT/AF burden of less than 5％ were excluded（because it is difficult to determine the effectiveness of treatment）as well as patients with only one episode. The effective group（5 patients）had higher prevalences of longer intracardiac AT/AF average tachycardia cycle length（AvCL）（＞300ms）（28.6％ vs 5.2％, p＜0.05）, organized atrial fibrillation（AF）and atrial tachycardia（AT）（71.9％ vs 48.5％, p＜0.05）, and history of catheter ablation（CA）or Maze surgery for AF（80％ vs 14％, p＜0.02）than those in the ineffective group（7 patients）. F wave CL of 12-lead ECGs was significantly larger in the effective group than in the ineffective group（220.5ms vs 141.4ms, p＜0.05）. A-ATP was effective in longer or organized AF and AT AvCL cases. A history of CA or Maze surgery and long F wave CL in 12-lead ECGs were confirmable predictors of A-ATP efficacy before device implantation.
